雷贝拉唑联合莫沙必利治疗胃食管反流病临床疗效观察及安全性分析

Curative Effect and Safety Analysis of Rabeprazole Combined with Mosapride in the Treatment of Gastroesophageal Reflux Disease

目的探讨雷贝拉唑联合莫沙必利治疗胃食管反流病的临床疗效及安全性。方法选取2014年6月至2015年6月重庆三峡中心医院收治的胃食管反流病患者82例,采用随机数字表法分为观察组和对照组,各41例。观察组采用雷贝拉唑(10 mg/次,2次/d,口服)联合莫沙必利(5 mg/次,3次/d,口服)治疗,对照组单独采用雷贝拉唑(10 mg/次,2次/d,口服)进行治疗,连续治疗2个月。比较两组临床疗效及不良反应发生情况。结果治疗2个月后观察组De Meester积分显著低于对照组[(12.2±1.8)分比(14.2±2.0)分,P<0.01]。观察组治疗总有效率显著高于对照组[95.1%(38/41)比80.5%(33/41)],P<0.05)。两组不良反应发生率比较差异无统计学意义[12.2%(5/41)比9.8%(4/41),P>0.05]。结论雷贝拉唑联合莫沙必利治疗胃食管反流病临床疗效好,安全性高,值得临床推广应用。

Objective To investigate the curative effect and safety of rabeprazole combined with mosa- pride in the treatment of gastroesophageal reflux disease. Methods From Jun. 2014 to Jun. 2015,82 patients with gastroesophageal reflux disease in Chongqing Three Gorges Central Hospital were divided into an observation group and a control group according to the random number table method,41 cases in each group. The observation group was treated with rabeprazole （10 mg/time,2 times/day, oral） combined with mosapride （10 mg/time ,2 times/day, oral）, and the control group was treated with rabeprazole（ 5 mg/time,3 times/ day,oral） ,continuously for 2 months. The clinical efficacy and adverse reactions of the two groups were com- pared. Results After 2 months of treatment,the DeMeester score of the observation group was significantly lower than the control group [ （ 12.2 ± 1.8 ） vs （ 14. 2 ±2 ） ,P 〈0. 01 ]. The total effective rate of the obser- vation group was significantly higher than the control group [ 95. 1% （ 38/41 ） vs 80. 5% （ 33/41 ）, P 〈 0. 05 ]. There was no significant difference in the incidence of adverse reactions between the two groups [ 12.2% （ 5/41 ） vs 9. 8% （ 4/41 ）, P 〉 0. 05 ]. Conclusion Rabeprazole combined with mosapride as treatment of astroesoohazeal reflux disease is safe and effective .thus is worthy of promotion in clinical.